A regulatory T cell, commonly abbreviated Treg, is a specialized T lymphocyte that suppresses immune responses and helps prevent immune-mediated damage to the body’s own tissues. Tregs are important components of the immune system and a major mechanism of peripheral immune tolerance. The best-characterized population consists of CD4-positive cells expressing the transcription factor FOXP3. These cells help maintain homeostasis by restraining other immune cells rather than directly eliminating pathogens. Their regulatory activity is essential for limiting autoimmunity and controlling inflammation. (pubmed.ncbi.nlm.nih.gov)
Identification and molecular characteristics
FOXP3 coordinates a gene-expression program associated with Treg identity and suppressive function. It is an intracellular protein, so detecting it generally requires fixing and permeabilizing cells. Human blood Tregs are commonly identified using a combination of CD4, high expression of CD25, and low expression of CD127. CD25 is the alpha chain of the receptor for interleukin-2, whereas CD127 is the alpha chain of the interleukin-7 receptor. Combining these markers permits enrichment of living cells for functional experiments or cell expansion. (pmc.ncbi.nlm.nih.gov)
No single marker identifies every human Treg unambiguously. Activated conventional T cells can express CD25, transiently express FOXP3, and reduce CD127 expression without acquiring durable suppressive activity. Consequently, interpretation depends on the activation state, tissue sampled, and marker combination. Flow cytometry is often supplemented by suppression assays, which test whether candidate Tregs inhibit responder-cell proliferation or cytokine production. (aacrjournals.org)
Stable lineage identity also involves epigenetic regulation. A regulatory region within the FOXP3 locus, termed the Treg-specific demethylated region, is characteristically demethylated in stable Tregs. Analysis of DNA methylation helps distinguish these cells from conventional T cells with activation-induced FOXP3 expression. FOXP3 expression and stable Treg lineage commitment are therefore related but not equivalent measurements. (pmc.ncbi.nlm.nih.gov)
Development and origins
Thymus-derived Tregs, abbreviated tTregs, develop in the thymus. Their development provides a route through which some self-reactive T cells acquire regulatory rather than conventional effector functions. The presence of developing thymic Tregs with partial demethylation of the Foxp3 regulatory region demonstrates that establishment of their stable molecular identity begins during thymic development. (pmc.ncbi.nlm.nih.gov)
Regulatory cells can also arise from conventional CD4-positive T cells outside the thymus. Cells generated in the body’s peripheral tissues are termed peripherally derived Tregs, or pTregs; cells generated under experimental culture conditions are commonly called induced Tregs, or iTregs. Experiments demonstrated that antigen-receptor stimulation together with transforming growth factor beta can induce Foxp3 expression and suppressive activity in initially nonregulatory mouse T cells. However, experimentally induced FOXP3 expression does not necessarily confer the same stability as naturally established Treg identity. (pmc.ncbi.nlm.nih.gov)
Mechanisms of immune suppression
Tregs use several mechanisms whose importance varies with the tissue and inflammatory setting. They can modify interactions between responding T cells and antigen-presenting cells, alter the availability of growth signals, and release immunoregulatory cytokines. Evidence from selective gene-deletion experiments indicates that these mechanisms are not interchangeable in every context. (pubmed.ncbi.nlm.nih.gov)
One major pathway involves CTLA-4, an immune checkpoint protein. CTLA-4 can capture the costimulatory proteins CD80 and CD86 from another cell’s surface and internalize them, a process called trans-endocytosis. Removing these proteins reduces the capacity of antigen-presenting cells to provide CD28-mediated costimulation to conventional T cells. (pubmed.ncbi.nlm.nih.gov)
Tregs can also suppress responses through cytokine deprivation. In experimental systems, reduced access to survival-promoting cytokines causes responding T cells to undergo apoptosis. Another pathway involves interleukin-10: mice lacking IL-10 specifically in Tregs develop dysregulated responses at environmental interfaces, including the colon and lungs, even though this deletion does not produce generalized systemic autoimmunity. (pubmed.ncbi.nlm.nih.gov)
Tissue functions and disease relevance
Tregs are functionally heterogeneous rather than a uniform population. Human thymic and peripheral Tregs include subsets differing in ICOS expression and their production of immunoregulatory molecules. Experimental studies have also identified tissue-associated populations with functions extending beyond suppression of immune-cell activation. (pmc.ncbi.nlm.nih.gov)
In mouse skeletal muscle, Tregs accumulate after injury and contribute to repair. They produce amphiregulin, a growth factor that supports muscle satellite-cell function. Separate experiments in influenza-infected mice showed that Treg-derived amphiregulin protects lung tissue without being required for suppression of the antiviral response. These findings distinguish tissue-protective activity from immune suppression, although the observations do not establish equivalent therapeutic effects in humans. (sciencedirect.com)
The importance of Treg-associated regulation in humans is illustrated by IPEX syndrome, an X-linked disorder caused by pathogenic FOXP3 variants. Its name denotes immune dysregulation, polyendocrinopathy, and enteropathy. The genetic association provides direct evidence linking disruption of FOXP3-dependent regulation to severe immune dysfunction. Tregs also occur in cancers, where their suppressive activity can contribute to reduced antitumor immune responses. (pubmed.ncbi.nlm.nih.gov)
Experimental and clinical investigation
Treg-based cell therapy has been investigated by isolating a patient’s own regulatory cells, expanding them outside the body, and reinfusing them. A phase 1 study published in 2015 tested expanded autologous Tregs in 14 adults with type 1 diabetes. It reported feasibility and no infusion reactions or cell-therapy-related high-grade adverse events. Its small, uncontrolled design did not establish clinical efficacy. Functional identity, stability during expansion, and persistence after infusion were important measurements in evaluating the cellular product. (pmc.ncbi.nlm.nih.gov)